# Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Source: https://onco.cc/trials/nct07448116/  
OnCo record `nct07448116` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MCLA-129 and Ensartinib in advanced solid tumours, run by Betta Pharmaceuticals Co., Ltd., now recruiting.

## Summary

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT07448116 by Betta Pharmaceuticals Co., Ltd., with 164 participants planned, started 2026-01-31 and due to reach its primary completion in 2029-02-01. Interventions recorded: MCLA-129 and Ensartinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07448116
- Phase: 1/2
- Setting: A Multi-cohort, Open-label Phase I/II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Combination With Ensartinib Hydrochloride in Patients With Advanced Solid Tumors.
- Sponsor: Betta Pharmaceuticals Co., Ltd.
- Enrolled: 164

## Sources

- ClinicalTrials.gov NCT07448116: https://clinicaltrials.gov/study/NCT07448116

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Ensartinib](https://onco.cc/drugs/ensartinib/), [MCLA-129](https://onco.cc/drugs/mcla-129/)
- companies: [Betta Pharmaceuticals](https://onco.cc/companies/betta/)

---
JSON: https://onco.cc/api/v1/entities/nct07448116.json